S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
Log in
NASDAQ:RTRX

Travere Therapeutics Stock Forecast, Price & News

$27.67
+0.79 (+2.94 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.34
Now: $27.67▼
$27.71
50-Day Range
$24.25
MA: $26.52▼
$28.18
52-Week Range
$8.98
Now: $27.67▼
$24.96
Volume341,346 shs
Average Volume412,277 shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.67
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Travere Therapeutics logo

MarketRank™

Overall MarketRank™

0.86 out of 5 stars

Medical Sector

1072nd out of 1,922 stocks

Pharmaceutical Preparations Industry

501st out of 769 stocks

Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
Previous Symbol
CUSIPN/A
CIK1438533
Webwww.retrophin.com
Phone(888) 969-7879
Employees221

Debt

Debt-to-Equity Ratio0.66
Current Ratio7.23
Quick Ratio7.14

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$175.34 million
Price / Sales8.06
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.15 per share
Price / Book5.37

Profitability

EPS (Most Recent Fiscal Year)($3.46)
Net Income$-146,430,000.00
Net Margins-49.13%
Return on Equity-36.38%
Return on Assets-14.90%

Miscellaneous

Outstanding Shares51,052,000
Market Cap$1.41 billion
Next Earnings Date2/22/2021 (Estimated)
OptionableOptionable
$27.67
+0.79 (+2.94 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Travere Therapeutics (NASDAQ:RTRX) Frequently Asked Questions

How has Travere Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Travere Therapeutics' stock was trading at $14.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RTRX stock has increased by 87.1% and is now trading at $27.67.
View which stocks have been most impacted by COVID-19.

Is Travere Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Travere Therapeutics stock.
View analyst ratings for Travere Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Travere Therapeutics?

Wall Street analysts have given Travere Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Travere Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Travere Therapeutics' next earnings date?

Travere Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Travere Therapeutics.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:RTRX) issued its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative net margin of 49.13% and a negative trailing twelve-month return on equity of 36.38%.
View Travere Therapeutics' earnings history.

What price target have analysts set for RTRX?

6 equities research analysts have issued 1 year target prices for Travere Therapeutics' stock. Their forecasts range from $21.00 to $33.00. On average, they anticipate Travere Therapeutics' share price to reach $28.00 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for Travere Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Travere Therapeutics' key competitors?

Some companies that are related to Travere Therapeutics include Blueprint Medicines (BPMC), Amicus Therapeutics (FOLD), Maravai LifeSciences (MRVI), Eidos Therapeutics (EIDX), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Arena Pharmaceuticals (ARNA), Atea Pharmaceuticals (AVIR), ChemoCentryx (CCXI), GW Pharmaceuticals (GWPH), FibroGen (FGEN), PTC Therapeutics (PTCT), Insmed (INSM) and Arvinas (ARVN).
View all of RTRX's competitors.

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Travere Therapeutics investors own include CVS Health (CVS), Gilead Sciences (GILD), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Novavax (NVAX), Sangamo Therapeutics (SGMO), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK) and Exelixis (EXEL).

Who are Travere Therapeutics' key executives?

Travere Therapeutics' management team includes the following people:
  • Eric Dube, President, Chief Executive Officer & Director
  • Laura M. Clague, Chief Financial & Accounting Officer
  • Bill Rote, Senior VP, Head-Research & Development
  • Noah L. Rosenberg, Chief Medical Officer
  • Elizabeth E. Reed, Secretary, Senior Vice President & General Counsel

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "RTRX."

How do I buy shares of Travere Therapeutics?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Travere Therapeutics' stock price today?

One share of RTRX stock can currently be purchased for approximately $27.67.

How big of a company is Travere Therapeutics?

Travere Therapeutics has a market capitalization of $1.41 billion and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Travere Therapeutics employs 221 workers across the globe.

What is Travere Therapeutics' official website?

The official website for Travere Therapeutics is www.retrophin.com.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (888) 969-7879 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.